International Registry on the Use of the Direct Oral Anticoagulants for the Treatment of Unusual Site Venous Thromboembolism
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 358
- 试验地点
- 24
- 主要终点
- Rationale for the use of the direct oral anticoagulants
研究概览
简要总结
Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis, ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators aim to evaluate the rationale for the use of the DOAC for the treatment of unusual site VTE and to assess the safety and effectiveness of this approach in real life clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Objective diagnosis of venous thrombosis not involving the upper limbs, lower limbs and pulmonary arteries
- •Treatment with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban)
排除标准
- •Enrolment in interventional studies evaluating the DOAC for the treatment of unusual site VTE
结局指标
主要结局
Rationale for the use of the direct oral anticoagulants
时间窗: Baseline
Possible reasons for choosing one of the direct oral anticoagulant (multiple choice question)
次要结局
- Rate of vascular events(12 months)
- Rate of major bleeding events(12 months)
研究者
Nicoletta Riva
Lecturer
University of Malta